GlassScriptPhysician profile
Haibo Cheng
NPI 1497488241
$23,837.12
in general payments reported to CMS, 2019-2025
33 companies · $8,009 in 2025
The $8,009 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.36 · 2023: $3,910 · 2024: $12K · 2025: $8,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21K · Consulting Fee: $2,310 · Education: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20,841.51 |
| Consulting Fee | $2,310.00 |
| Education | $660.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,644.53 | 2023-2025 | |
| Genzyme Corporation | $2,202.51 | 2023-2025 | |
| Dermavant Sciences, INC. | $1,911.58 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $1,789.38 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $1,431.95 | 2023-2025 | Ilumya |
| Incyte Corporation | $1,386.66 | 2024-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $1,252.42 | 2023-2025 | Dupixent |
| Medimetriks Pharmaceuticals, INC. | $1,243.30 | 2023-2025 | Clindacin Etz, Neuac, Neo-Synalar |
| Arcutis Biotherapeutics, INC. | $1,179.96 | 2023-2025 | Zoryve |
| Ucb, INC. | $955.64 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $950.67 | 2024 | Cabtreo, Duobrii, Arazlo |
| Janssen Biotech, INC. | $876.59 | 2024-2025 | Tremfya |
| Pfizer INC. | $864.13 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $761.06 | 2024-2025 | |
| Organon LLC | $609.00 | 2023-2025 | Vtama, Hadlima |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $513.54 | 2023-2025 | |
| Leo Pharma INC. | $507.16 | 2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $470.05 | 2024-2025 | Nemluvio, Aklief |
| Janssen Scientific Affairs, LLC | $465.23 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $457.84 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Mayne Pharma Commercial LLC | $330.46 | 2023-2025 | |
| Amgen INC. | $194.86 | 2023-2024 | Otezla, Enbrel |
| Bayer Healthcare Pharmaceuticals INC. | $167.32 | 2024 | |
| Botanix Sb INC | $161.85 | 2025 | Sofdra |
| Averitas Pharma INC. | $155.88 | 2024 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.62 | 2022-2024 | Spevigo |
| Fresenius Kabi USA, LLC | $71.62 | 2023 | Idacio |
| Almirall LLC | $50.20 | 2023-2024 | Klisyri |
| Verrica Pharmaceuticals INC. | $48.81 | 2024 | Ycanth |
| Sandoz INC. | $27.54 | 2025 | Hyrimoz |
| Cipher Pharmaceuticals US LLC | $26.35 | 2025 | Spinosad, Natroba |
| Lifenet Health | $25.84 | 2025 | Theragenesis Wound Matrix |
| Sebela Pharmaceuticals INC. | $20.57 | 2023 | Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haibo Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.